Hereditary breast and ovarian cancer – University Hospital of Split experiences

• Published in: Libri oncologici Vol. 51; no. 1; pp. 9 - 19
• Main Authors: Petrić-Miše, Branka, Katalenić, Monika, Hrepić, Darijo, Kuret, Sendi, Drmić-Hofman0000-0002-4986-9589, Irena
• Format: Journal Article
• Language: English
• Published: University Hospital for Tumors 2023
• Subjects: BRCA mutations; breast and ovarian cancer; outcomes
• ISSN: 0300-8142; 2584-3826
• DOI: 10.20471/LO.2023.51.01.02

Aim: To investigate the clinical and pathohistological tumor characteristics, treatment, and treatment outcomes in patients with hereditary breast and ovarian cancer who were diagnosed, treated, and monitored at the University Hospital of Split from October 1999 to April 2021. Methods: The data were collected retrospectively from the medical history of 15 patients. They included the patient’s age at diagnosis, family history of malignancies, histological subtype, grade, breast cancer immunophenotype, stage of disease, status and types of BRCA mutations, type of surgical and oncological treatment, the specifics of metachronous bilateral breast cancers, the specifics of synchronous breast and ovarian cancers, and the outcome of treatment through overall survival (OS). Results: The median age of patients at the time of diagnosis of breast cancer was 53 years, and for ovarian cancer it was 56 years. A positive family history was confirmed in 13 patients (87%). All ovarian cancer patients had a high-grade serous histologic type, most often diagnosed in FIGO stages III and IV. Breast cancers were most commonly diagnosed in stages IA and IIA, with equally represented triple-negative and luminal immunophenotypes. The most common mutation was BRCA1 c.5266dup. The median OS of our patients was not reached. Conclusion: The clinical features of patients, pathohistological characteristics of tumors, and treatment outcomes in our study population are comparable with reports in the literature, respecting the specifics of different nations and race